| J05AP |
J05AP Antivirals for treatment of HCV infections |
| J05AP01 |
J05AP01 Ribavirin |
| J05AP02 |
J05AP02 Telaprevir |
| J05AP03 |
J05AP03 Boceprevir |
| J05AP04 |
J05AP04 Faldaprevir |
| J05AP05 |
J05AP05 Simeprevir |
| J05AP06 |
J05AP06 Asunaprevir |
| J05AP07 |
J05AP07 Umifenovir |
| J05AP08 |
J05AP08 Sofosbuvir |
| J05AP09 |
J05AP09 Dasabuvir |
| J05AP10 |
J05AP10 Elbasvir |
| J05AP11 |
J05AP11 Grazoprevir |
| J05AP51 |
J05AP51 Sofosbuvir And Ledipasvir |
| J05AP52 |
J05AP52 Dasabuvir, ombitasvir, paritaprevir and ritonavir |
| J05AP53 |
J05AP53 ombitasvir, paritaprevir and ritonavir |
| J05AP54 |
J05AP54 elbasvir and grazoprevir |
| J05AP55 |
J05AP55 Sofosbuvir and velpatasvir |
| J05AP56 |
J05AP56 Sofosbuvir, velpatasvir and voxilaprevir |
| J05AP57 |
J05AP57 glecaprevir and pibrentasvir |
| J05AP58 |
J05AP58 Daclatasvir, Asunaprevir And Beclabuvir |
| J05AR |
J05AR Antivirals for treatment of HIV infections, combinations |
| J05AR01 |
J05AR01 zidovudine and lamivudine |
| J05AR02 |
J05AR02 Lamivudine and abacavir |
| J05AR03 |
J05AR03 tenofovir disoproxil and emtricitabine |
| J05AR04 |
J05AR04 zidovudine, lamivudine and abacavir |
| J05AR05 |
J05AR05 zidovudine, lamivudine and nevirapine |
| J05AR06 |
J05AR06 emtricitabine, tenofovir disoproxil and efavirenz |
| J05AR07 |
J05AR07 stavudine, lamivudine and nevirapine |
| J05AR08 |
J05AR08 emtricitabine, tenofovir disoproxil and Rilpivirine |
| J05AR09 |
J05AR09 emtricitabine, tenofovir disoproxil, elvitegravir and cobicistat |